Quantifying the Excess Risk of Adverse COVID-19 Outcomes in Unvaccinated Individuals With Diabetes Mellitus, Hypertension, Ischaemic Heart Disease or Myocardial Injury: A Meta-Analysis.
COVID-19
adverse outcomes
cardiovascular risk factors
diabetes
hypertension
ischaemic heart disease
myocardial injury
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2022
2022
Historique:
received:
07
02
2022
accepted:
01
04
2022
entrez:
13
5
2022
pubmed:
14
5
2022
medline:
14
5
2022
Statut:
epublish
Résumé
More than 80% of individuals in low and middle-income countries (LMICs) are unvaccinated against coronavirus disease 2019 (COVID-19). In contrast, the greatest burden of cardiovascular disease is seen in LMIC populations. Hypertension (HTN), diabetes mellitus (DM), ischaemic heart disease (IHD) and myocardial injury have been variably associated with adverse COVID-19 outcomes. A systematic comparison of their impact on specific COVID-19 outcomes is lacking. We quantified the impact of DM, HTN, IHD and myocardial injury on six adverse COVID-19 outcomes: death, acute respiratory distress syndrome (ARDS), invasive mechanical ventilation (IMV), admission to intensive care (ITUadm), acute kidney injury (AKI) and severe COVID-19 disease (SCov), in an unvaccinated population. We included studies published between 1 We included 110 studies comprising 48,809 COVID-19 patients. Myocardial injury had the strongest association for all six adverse COVID-19 outcomes [death: OR 8.85 95% CI (8.08-9.68), ARDS: 5.70 (4.48-7.24), IMV: 3.42 (2.92-4.01), ITUadm: 4.85 (3.94-6.05), AKI: 10.49 (6.55-16.78), SCov: 5.10 (4.26-6.05)]. HTN and DM were also significantly associated with death, ARDS, ITUadm, AKI and SCov. There was substantial heterogeneity in the results, partly explained by differences in age, gender, geographical region and recruitment period. COVID-19 patients with myocardial injury are at substantially greater risk of death, severe disease and other adverse outcomes. Weaker, yet significant associations are present in patients with HTN, DM and IHD. Quantifying these associations is important for risk stratification, resource allocation and urgency in vaccinating these populations. https://www.crd.york.ac.uk/prospero/, registration no: CRD42020201435 and CRD42020201443.
Sections du résumé
Background
UNASSIGNED
More than 80% of individuals in low and middle-income countries (LMICs) are unvaccinated against coronavirus disease 2019 (COVID-19). In contrast, the greatest burden of cardiovascular disease is seen in LMIC populations. Hypertension (HTN), diabetes mellitus (DM), ischaemic heart disease (IHD) and myocardial injury have been variably associated with adverse COVID-19 outcomes. A systematic comparison of their impact on specific COVID-19 outcomes is lacking. We quantified the impact of DM, HTN, IHD and myocardial injury on six adverse COVID-19 outcomes: death, acute respiratory distress syndrome (ARDS), invasive mechanical ventilation (IMV), admission to intensive care (ITUadm), acute kidney injury (AKI) and severe COVID-19 disease (SCov), in an unvaccinated population.
Methodology
UNASSIGNED
We included studies published between 1
Results
UNASSIGNED
We included 110 studies comprising 48,809 COVID-19 patients. Myocardial injury had the strongest association for all six adverse COVID-19 outcomes [death: OR 8.85 95% CI (8.08-9.68), ARDS: 5.70 (4.48-7.24), IMV: 3.42 (2.92-4.01), ITUadm: 4.85 (3.94-6.05), AKI: 10.49 (6.55-16.78), SCov: 5.10 (4.26-6.05)]. HTN and DM were also significantly associated with death, ARDS, ITUadm, AKI and SCov. There was substantial heterogeneity in the results, partly explained by differences in age, gender, geographical region and recruitment period.
Conclusion
UNASSIGNED
COVID-19 patients with myocardial injury are at substantially greater risk of death, severe disease and other adverse outcomes. Weaker, yet significant associations are present in patients with HTN, DM and IHD. Quantifying these associations is important for risk stratification, resource allocation and urgency in vaccinating these populations.
Systematic Review Registration
UNASSIGNED
https://www.crd.york.ac.uk/prospero/, registration no: CRD42020201435 and CRD42020201443.
Identifiants
pubmed: 35557537
doi: 10.3389/fcvm.2022.871151
pmc: PMC9090337
doi:
Types de publication
Systematic Review
Langues
eng
Pagination
871151Informations de copyright
Copyright © 2022 Ng, Pan, Mouyis, Kondapally Seshasai, Kapil, Rice and Gupta.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
SN Compr Clin Med. 2020;2(10):1740-1749
pubmed: 32904541
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Front Immunol. 2020 Jun 16;11:1446
pubmed: 32612617
Acad Emerg Med. 2020 Jun;27(6):461-468
pubmed: 32311790
Diabetes Care. 2020 Jul;43(7):1408-1415
pubmed: 32430456
J Diabetes. 2020 Dec;12(12):868-869
pubmed: 32969135
Cardiovasc Diabetol. 2021 May 7;20(1):99
pubmed: 33962629
J Infect. 2020 Jun;80(6):639-645
pubmed: 32240670
Nat Med. 2020 Jul;26(7):1017-1032
pubmed: 32651579
Hypertension. 2021 Mar 3;77(3):846-855
pubmed: 33325240
Diabetes Metab. 2020 Oct;46(5):403-405
pubmed: 32447102
Lancet Diabetes Endocrinol. 2020 Oct;8(10):823-833
pubmed: 32798471
Rev Diabet Stud. 2018 Nov 23;15:1-15
pubmed: 30489598
ESC Heart Fail. 2020 Oct 2;:
pubmed: 33006440
Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Jul 24;48(7):567-571
pubmed: 32141280
J Cardiovasc Dev Dis. 2021 Nov 25;8(12):
pubmed: 34940517
Lancet. 2021 May 22;397(10288):1885-1894
pubmed: 34022988
Crit Care. 2020 Aug 27;24(1):525
pubmed: 32854750
Nat Rev Endocrinol. 2021 Jan;17(1):11-30
pubmed: 33188364
MMWR Morb Mortal Wkly Rep. 2022 Feb 04;71(5):177-181
pubmed: 35113851
J Clin Med. 2020 May 11;9(5):
pubmed: 32403217
Trends Immunol. 2020 Dec;41(12):1100-1115
pubmed: 33132005
Biometrika. 2010 Jun;97(2):321-332
pubmed: 23049122
Front Public Health. 2021 Jul 01;9:600878
pubmed: 34277531
Res Synth Methods. 2020 May;11(3):387-396
pubmed: 32092228
J Med Virol. 2022 May;94(5):2160-2166
pubmed: 35050521
Front Physiol. 2021 May 03;12:665064
pubmed: 34012410
JAMA Cardiol. 2020 Jul 1;5(7):802-810
pubmed: 32211816
Ann Am Thorac Soc. 2020 Jul;17(7):839-846
pubmed: 32255382
Front Immunol. 2021 Apr 28;12:589095
pubmed: 33995341
Cardiovasc Diabetol. 2020 Jun 11;19(1):76
pubmed: 32527257
JAMA. 2022 Apr 5;327(13):1247-1259
pubmed: 35315874
Hypertension. 2021 Mar 3;77(3):833-842
pubmed: 33423528
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120